Omnicell Inc
Research Omnicell Inc (OMCL) on Bullrun: valuation model: 7.6% overvalued, market cap USD 1.52B, P/E 39.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOMCL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyUSD
- Valuation signal7.6% overvalued
- Market capUSD 1.52B
- P/E39.3
- Financial periodQ2 2026
- RevenueUSD 312.21M
- Net incomeUSD 24.29M
- Free cash flowUSD 55.78M
- Gross margin49.0%
Valuation Snapshot
Bullrun's latest valuation model marks Omnicell Inc as 7.6% overvalued; latest market cap is USD 1.52B; P/E is 39.3.
Peer valuation comparison
Latest P/E is 39.28x versus a Healthcare sector median of 24.46x (60.6% above).
Latest P/E is 39.28x versus a United States median of 24.87x (58.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.18B | USD 2.05M | USD 86.89M | 42.5% | 0.04 | USD 196.52M | USD 204.35M | USD 1.23B |
| FY2024 | USD 1.11B | USD 12.53M | USD 151.26M | 42.3% | 0.27 | USD 369.20M | USD 382.55M | USD 1.24B |
| FY2023 | USD 1.15B | -USD 20.37M | USD 139.62M | 43.3% | -0.45 | USD 467.97M | USD 614.09M | USD 1.19B |
| FY2022 | USD 1.30B | USD 5.65M | USD 30.25M | 45.4% | 0.12 | USD 330.36M | USD 607.67M | USD 1.13B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.52B | 39.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.04B | 1132.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.06B | 171.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.71B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.25B | 49.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.97B | 110.7 | n/a | n/a |
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Omnicell Inc overvalued or undervalued?
Bullrun's valuation model currently marks Omnicell Inc as 7.6% overvalued.
What is Omnicell Inc's market cap?
Omnicell Inc's market capitalization is USD 1.52B.
What is Omnicell Inc's P/E ratio?
Omnicell Inc's price-to-earnings (P/E) ratio is 39.3.
What does Omnicell Inc do?
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.